Cargando…

Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China

The objective of this study was to estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) among people with malignancies in China. The WTP for a QALY was estimated using a contingent valuation survey. Health utility was measured in EuroQol-5 dimensions (EQ-5D). The questionnaire...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li, Peng, Xiaochen, Sun, Lihua, Zhang, Dawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243056/
https://www.ncbi.nlm.nih.gov/pubmed/37277820
http://dx.doi.org/10.1186/s12962-023-00442-y
_version_ 1785054349450280960
author Huang, Li
Peng, Xiaochen
Sun, Lihua
Zhang, Dawei
author_facet Huang, Li
Peng, Xiaochen
Sun, Lihua
Zhang, Dawei
author_sort Huang, Li
collection PubMed
description The objective of this study was to estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) among people with malignancies in China. The WTP for a QALY was estimated using a contingent valuation survey. Health utility was measured in EuroQol-5 dimensions (EQ-5D). The questionnaires were completed in face-to-face interviews. Respondents consisted of patients with malignant tumors and their family members and came from three tertiary hospitals in different cities with high, medium, and low gross domestic product (GDP) levels. In this study, we offered lump-sum payments and 10 year installment plans to respondents. Finally, we conducted sensitivity analysis and stepwise regression analyses to identify factors that affected the WTP/QALY ratios. A total of 1264 people participated in this survey, and 1013 people gave WTP responses for further analysis. The mean and median WTP/QALY values based on the lump-sum payments were 366,879 RMB (53,171USD, 5.1 times the GDP per capita) and 99,906 RMB (14,479USD, 1.39 times the GDP per capita) for the overall sample; 339,330 RMB (49,178USD, 4.71 times the GDP per capita) and 83,875 RMB (12,156USD, 1.16 times the GDP per capita) for the patient group; and 407,396 RMB (59,043USD, 5.66 times the GDP per capita) and 149,436 RMB (21,657USD, 2.08 times the GDP per capita) for the family group. Considering the skewedness of the data distribution, we suggest setting the cost-utility threshold with reference to the median. When the payment plan changed to 10-year installments, the median increased to 134,734RMB (19,527USD), 112,390 RMB (16,288USD) and 173,838 RMB (25,194USD) for the above groups, respectively. EQ-5D-5L health utility, annual household income per capita, patients with other chronic diseases, occupation, regular physical examinations (patients) and age (family members) were significantly related to WTP/QALY. This study provides empirical evidence of the monetary value of a QALY from a sample of the Chinese population with malignancies. In addition, the ratio of the WTP/QALY to GDP per capita was related to the disease and hypothetical scenario, and a higher ratio of GDP per capita for malignant tumor therapies should be considered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-023-00442-y.
format Online
Article
Text
id pubmed-10243056
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102430562023-06-07 Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China Huang, Li Peng, Xiaochen Sun, Lihua Zhang, Dawei Cost Eff Resour Alloc Research The objective of this study was to estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) among people with malignancies in China. The WTP for a QALY was estimated using a contingent valuation survey. Health utility was measured in EuroQol-5 dimensions (EQ-5D). The questionnaires were completed in face-to-face interviews. Respondents consisted of patients with malignant tumors and their family members and came from three tertiary hospitals in different cities with high, medium, and low gross domestic product (GDP) levels. In this study, we offered lump-sum payments and 10 year installment plans to respondents. Finally, we conducted sensitivity analysis and stepwise regression analyses to identify factors that affected the WTP/QALY ratios. A total of 1264 people participated in this survey, and 1013 people gave WTP responses for further analysis. The mean and median WTP/QALY values based on the lump-sum payments were 366,879 RMB (53,171USD, 5.1 times the GDP per capita) and 99,906 RMB (14,479USD, 1.39 times the GDP per capita) for the overall sample; 339,330 RMB (49,178USD, 4.71 times the GDP per capita) and 83,875 RMB (12,156USD, 1.16 times the GDP per capita) for the patient group; and 407,396 RMB (59,043USD, 5.66 times the GDP per capita) and 149,436 RMB (21,657USD, 2.08 times the GDP per capita) for the family group. Considering the skewedness of the data distribution, we suggest setting the cost-utility threshold with reference to the median. When the payment plan changed to 10-year installments, the median increased to 134,734RMB (19,527USD), 112,390 RMB (16,288USD) and 173,838 RMB (25,194USD) for the above groups, respectively. EQ-5D-5L health utility, annual household income per capita, patients with other chronic diseases, occupation, regular physical examinations (patients) and age (family members) were significantly related to WTP/QALY. This study provides empirical evidence of the monetary value of a QALY from a sample of the Chinese population with malignancies. In addition, the ratio of the WTP/QALY to GDP per capita was related to the disease and hypothetical scenario, and a higher ratio of GDP per capita for malignant tumor therapies should be considered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-023-00442-y. BioMed Central 2023-06-05 /pmc/articles/PMC10243056/ /pubmed/37277820 http://dx.doi.org/10.1186/s12962-023-00442-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Li
Peng, Xiaochen
Sun, Lihua
Zhang, Dawei
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title_full Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title_fullStr Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title_full_unstemmed Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title_short Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China
title_sort estimation of the value of curative therapies in oncology: a willingness-to-pay study in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243056/
https://www.ncbi.nlm.nih.gov/pubmed/37277820
http://dx.doi.org/10.1186/s12962-023-00442-y
work_keys_str_mv AT huangli estimationofthevalueofcurativetherapiesinoncologyawillingnesstopaystudyinchina
AT pengxiaochen estimationofthevalueofcurativetherapiesinoncologyawillingnesstopaystudyinchina
AT sunlihua estimationofthevalueofcurativetherapiesinoncologyawillingnesstopaystudyinchina
AT zhangdawei estimationofthevalueofcurativetherapiesinoncologyawillingnesstopaystudyinchina